Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway

Ni Wang,Lu Zhang,Xiao-Xu Leng,Yi-Le Xie,Zi-Ran Kang,Li-Cong Zhao,Lin-Hong Song,Cheng-Bei Zhou,Jing-Yuan Fang
DOI: https://doi.org/10.1080/19490976.2024.2333790
IF: 12.2
2024-03-29
Gut Microbes
Abstract:Chemotherapy resistance is one of the main reasons for the poor prognosis of colorectal cancer (CRC). Moreover, dysbiosis of gut bacteria was found to be a specific environmental risk factor. In this study, enrichment of F. nucleatum was elucidated to be significantly associated with CRC recurrence after chemotherapy. Functional experiments showed that F. nucleatum could inhibit pyroptosis induced by chemotherapy drugs, thereby inducing chemoresistance. Furthermore, mechanistic investigation demonstrated that F. nucleatum could regulate the Hippo pathway and promote the expression of BCL2, thereby inhibiting the Caspase-3/GSDME pyroptosis-related pathway induced by chemotherapy drugs and mediating CRC cell chemoresistance. Taken together, these results validated the significant roles of F. nucleatum in CRC chemoresistance, which provided an innovative theoretical basis for the clinical diagnosis and therapy of CRC.
gastroenterology & hepatology,microbiology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is **to explore the mechanism of action of Fusobacterium nucleatum (F. nucleatum) in chemotherapy resistance in colorectal cancer (CRC)**. Specifically, the researchers found that Fusobacterium nucleatum can lead to CRC resistance to chemotherapy by inhibiting chemotherapy - induced pyroptosis. Further mechanism studies have shown that Fusobacterium nucleatum can promote the expression of BCL2 by regulating the Hippo signaling pathway, thereby inhibiting the Caspase - 3/GSDME - related pyroptosis pathway induced by chemotherapy drugs, and ultimately leading to chemotherapy resistance in CRC cells. ### Main research contents and findings: 1. **The relationship between Fusobacterium nucleatum and CRC progression and prognosis**: The study found that the enrichment degree of Fusobacterium nucleatum in CRC tissues of relapsed patients was significantly higher than that in non - relapsed patients, and its abundance was positively correlated with tumor size and was associated with shortened relapse - free survival (RFS). 2. **Fusobacterium nucleatum inhibits chemotherapy - induced pyroptosis**: Through a series of functional experiments, the researchers demonstrated that Fusobacterium nucleatum can inhibit GSDME - related pyroptosis induced by chemotherapy drugs, which is manifested as reduced cell swelling, decreased cell membrane pore formation, and reduced lactate dehydrogenase (LDH) release. 3. **BCL2 is involved in Fusobacterium nucleatum - inhibiting chemotherapy - induced pyroptosis**: The study found that Fusobacterium nucleatum inhibits chemotherapy - induced pyroptosis by up - regulating the expression of BCL2. Knockdown of BCL2 can reverse the inhibitory effect of Fusobacterium nucleatum on pyroptosis. 4. **Fusobacterium nucleatum induces chemotherapy resistance by regulating the Hippo pathway**: Further research has shown that Fusobacterium nucleatum can activate the Hippo pathway, promote the binding of YAP to the BCL2 promoter region, thereby up - regulating the expression of BCL2, inhibiting the Caspase - 3/GSDME - related pyroptosis pathway, and ultimately leading to chemotherapy resistance in CRC cells. ### Conclusion: This study reveals the mechanism by which Fusobacterium nucleatum inhibits chemotherapy - induced pyroptosis by regulating the Hippo pathway and BCL2 expression, thereby leading to chemotherapy resistance in colorectal cancer. These findings not only provide a new perspective for understanding the molecular mechanism of chemotherapy resistance in colorectal cancer but also provide potential targets for the development of new treatment strategies.